GlobeNewswire

Cisco Doubles Down on Security Innovation and Investment to Protect the Endpoint and Email

Dela

Cisco Introduces New Email Security Services to More Effectively Prevent Phishing and Spoofing Attacks

 

SAN FRANCISCO, April 16, 2018 (GLOBE NEWSWIRE) -- RSA - Employees remain an organization's greatest asset however they can be a risk when it comes to cybersecurity. Attackers are crafting highly targeted, fraudulent emails that look legitimate and use them to deliver malware to unsuspecting users. When successful, it costs the majority of companies $500K or more in lost revenue, customers, opportunities, and out-of-pocket costs.1 To combat the rise of advanced threats targeting employees, Cisco is announcing new email security services to protect users from these fraudulent emails, as well as new capabilities to protect employees' devices from ransomware, cryptomining, and fileless malware.

Nearly all endpoint security solutions on the market claim to block 99 percent of malware. But what about the one percent of threats that evade detection using sophisticated techniques? Cisco® Advanced Malware Protection (AMP) for Endpoints, a cloud-managed endpoint security solution, prevents attacks and helps uncover the one percent of threats that can cripple a business. Cisco is adding a number of new capabilities to AMP for Endpoints, including:

  • Sophisticated detection and protection mechanisms to stop today's threats, including ransomware, and cryptomining: Cisco is now bolstering its threat protection even when a user is offline. The new AMP for Endpoints exploit prevention helps protect against fileless attacks, including those that reside solely in memory. Cisco AMP's new malicious activity protection stops ransomware execution, killing the processes and preventing propagation.
    • Cisco threat researchers analyzed ransomware variants to identify the common techniques used for encryption. The result: a new engine that continuously protects against ransomware encryption and propagation to keep businesses safe from ransomware.
    • Fileless malware has recently gained popularity in part because of the difficulty in detecting it. Built directly into the foundation of Cisco AMP is a new protection mechanism that requires no tuning or adjustments to stop these threats. It protects against unpatched software vulnerabilities and keeps working around the clock, even when users are offline. 
       
  • Threat investigation with Cisco Visibility, a new cloud application built into the endpoint console which simplifies and accelerates security investigations so security analysts can rapidly investigate incidents with confidence, quickly and at scale. It ingests, normalizes, and enriches security events and provides a visual representation of the extent of a compromise spanning from endpoints to network to cloud.
    • Cisco Visibility combines threat intelligence from Cisco Talos(TM) and third parties with internal security event and alert data from across an organization's security infrastructure to simplify investigations, reduce complexity, and shorten incident triage and remediation time.
    • Visibility minimizes the need to switch between multiple consoles to perform common tasks. With a few simple clicks, a user can dive deeper into the data from Talos, Cisco Umbrella Investigate(TM), Threat Grid, AMP, and other sources to quickly understand how observables exist in an environment and how they relate to each other.

Cisco invests in new email security services 
No matter how much the threat landscape changes, malicious email and spam remain vital tools for adversaries to distribute malware, and many of these threats reach the endpoint. Organizations must protect their own company domains from being misused as the delivery mechanism of malicious emails, as well as protect their internal users from phishing and spoofing attacks from emails with suspect senders.

Cisco is helping address these issues and more effectively prevent email identity deception used in phishing attacks. Cisco has concluded an OEM agreement with Agari to market and sell new services that enhance its Email Security product. The new email security services introduced include:

  • Cisco Domain Protection: Automates the process of using email authentication to prevent phishing, protect brands from fraud, and maintain email governance by analyzing, updating, and taking action against senders misusing their domain to send malicious email. This service uses Domain-Based Message Authentication, Reporting, and Conformance (DMARC), an email authentication standard, and real-time reporting back to domain users about noncompliant emails being sent from their domains. This will be a requirement for many organizations in the future, and as of October 2017, the U.S. Department of Homeland Security ordered federal agencies with .gov email domains to fully implement strict DMARC policies by October 2018.
  • Cisco Advanced Phishing Protection: Adds sophisticated machine learning capabilities to Cisco Email Security to block advanced identity deception attacks for inbound email by assessing its threat posture. It also uses both global and local telemetry data combined with analytics and modeling to validate the reputation and authenticity of senders. This helps organizations understand which emails carry targeted phishing and business email compromise (BEC) attacks so only legitimate emails reach an employee inbox.

Deployment through managed security services
To enable customers of all sizes to realize the benefits of these new capabilities, Cisco is expanding its relationship with ConnectWise so managed service providers (MSP) can offer Cisco Security as a part of their portfolio. The expanded relationship will offer the new ConnectWise Advanced Security Dashboard. This cloud management platform fully integrates with the ConnectWise Manage business management solution and complements ConnectWise Unite with Cisco, the existing portal for MSPs based on leading Cisco cloud-managed products. The new ConnectWise Advanced Security Dashboard provides MSPs with the ability to deliver managed security services with Cisco's security portfolio including Cisco AMP for Endpoints,  Cisco Umbrella, Cisco Stealthwatch® Cloud, Cisco Adaptive Security Appliances, Cisco Next-Generation Firewall, and Cisco Meraki® MX appliances.

"Cisco understands that protecting employees and their endpoints requires more than just antivirus. Attackers leverage the Internet, email, and the network as vectors for breaching the endpoint," said Jeff Reed, Senior Vice President of Product for Cisco's Security Business Group. "We deliver greater employee protection using cloud-delivered defense against threats hosted on the Internet. Cisco is also now one of the few organizations paving the way toward eliminating email identity deception. Through our expanded partnership, investments, and technology innovations, we are committed to delivering to our customers the best email and endpoint protection."

Supporting Resources:

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. 

_________________________
1 Cisco Annual Cybersecurity Report 2018.

Press Relations 
Raquel Prieto 
408-527-3754 
raqpriet@cisco.com 

Analyst Relations
Jenna Duston 
408-424 7210 
jeabeyta@cisco.com 

Investor Relations
Marty Palka 
408-526 6635
mpalka@cisco.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum